ChemGenex Appoints Donald Santel to Board of Directors
MELBOURNE, Australia, and MENLO PARK, California U.S.A.
December 06, 2007
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced that Mr. Donald Santel, former Chief Executive Officer of CoTherix Inc., has joined the company’s Board of Directors. Mr. Santel is an experienced senior executive and director with more than 25 years experience in the biotechnology, pharmaceutical and medical device industries.
As Chief Executive Officer of CoTherix Inc., over a period of seven years, Mr. Santel guided a small private company through several financing rounds and completed an initial public offering on Nasdaq. During that period he also led successful in-licensing efforts for two drugs, fostering one of these through FDA approval. He eventually negotiated the cash acquisition of CoTherix by Actelion in late 2006.
“As omacetaxine mepesuccinate moves from clinical trials toward FDA submission Don’s marketing, commercialization and corporate development experience will be an invaluable asset for us" said Greg Collier, Ph.D., Chief Executive Officer and Managing Director. “We welcome Donald to the Board of Directors and look forward to his contributions across the organization.”
“I am delighted to be joining ChemGenex at a pivotal period in the company’s development”, Mr. Santel said. “As omacetaxine completes late stage clinical trials and ChemGenex’s other clinical and preclinical cancer assets are progressed I look forward to working with both my fellow Directors and management to build and realize the value within these assets.”
About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing personalized oncology medicines. ChemGenex harnesses the power of genomics both to discover novel targets and drug compounds, and in clinical trials to develop more individualized treatment outcomes. ChemGenex’s lead compound, omacetaxine mepesuccinate (formerly known as Ceflatonin®), is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) where it has demonstrated single-agent efficacy against drug-resistant disease, as well as synergistic activity with the leading marketed compound. ChemGenex has a second anticancer compound, amonafide dihydrochloride (formerly known as Quinamed®) which is in phase 2 clinical development for various solid cancers, and a portfolio of assets in pre-clinical development. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP".
Contacts
| ChemGenex Information |
Media Relations |
| Dr. Greg Collier |
Daniella Goldberg |
| CEO and Managing Director |
Buchan Consulting |
| Cell (Australia): +61 419 897 501 |
Tel: +61 2 9237 2803 |
| Cell (USA): +1 650 200 8145 |
Cell: +61 416 211 067 |
| Email: gcollier@chemgenex.com |
Email: dgoldberg@bcg.com.au |
|
| |
|
| Investor Relations - Australia |
Investor Relations - USA |
| Sabrina Antoniou |
Dan Klein |
| Blueprint Life Science Group |
Blueprint Life Science Group |
| Tel:+61 400 788 277 |
Tel: +1 415 375 3340 Ext. 2024 |
| Email: santoniou@bplifescience.com |
Email: dklein@bplifescience.com |
Safe Harbor Statement
Certain statements made herein that use the words “estimate”, “project”, “intend”, “expect”, “believe”, and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company’s technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company’s technology, the market for the company’s products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management’s current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
